# L9LS in Women of Childbearing Potential in Mali

> **NCT07060508** · PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 290 (estimated)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** Single dose of 1800 mg L9LS SC
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07060508
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07060508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07060508, "L9LS in Women of Childbearing Potential in Mali". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07060508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*